Pharmaceutical Research Associates Group B.V.
Verified site
Groningen, The Netherlands
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study involves healthy adult volunteers and focuses on a rare heart condition called Cardiac arrhythmias, which means the heart beats irregularly. The medication being tested is an oral tablet named ARM210, given at a dose of 400 mg each day for ten days, and it is compared with a placebo tablet that contains lactose but no active drug. The purpose of the study is to assess the safety, tolerability, and pharmacokinetics—how the drug is absorbed, distributed, metabolized, and eliminated—of repeat doses of the test medication.
Participants will be randomly assigned to receive either the study drug or the placebo, taking one tablet each day for ten consecutive days. Throughout the study, volunteers will have regular check‑ups that include blood tests, measurements of vital signs such as blood pressure and heart rate, a physical examination, and a heart test called a 12-lead electrocardiogram, which records the electrical activity of the heart. Any side effects, changes in laboratory results, or abnormalities in the heart test will be recorded to evaluate how well the medication is tolerated.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
11 criteria
15 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Groningen, The Netherlands
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
ARM210 is an experimental oral tablet being studied for its safety and how well people can tolerate it. In this trial, healthy adult volunteers took the tablet once a day for ten days. Researchers are looking at how the drug is processed in the body and checking for any side effects or problems that might occur during the short‑term use.
These are plain tablets made of lactose that are taken by mouth and used only as a control in the study. They do not contain any active drug and therefore have no therapeutic use in medicine. Because they are inert, they are not listed in medical literature as a treatment. Their role is to help compare the effects of the test drug against a neutral substance.
ARM210 is an oral tablet taken by mouth, with each dose containing 400 mg of the active ingredient. It is an experimental medication that is still being studied and is not yet approved for clinical use. The drug is being tested for treating irregular heartbeats (cardiac arrhythmias) and works by gently blocking calcium signals in heart cells, which helps the heart beat more regularly. It belongs to the class of calcium‑channel blocker anti‑arrhythmic agents.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.